Gene expression patterns during heart development differ significantly between humans and mice, highlighting the need for careful comparative analyses for myocardial replacement therapies.
Answers are grounded in this paper and cite their sources.
Species differences in cardiac markers caution against mouse model extrapolation; leaves open human validation of Mlc-2v for myocardial therapies.
Although in mice, the dynamics of gene expression during heart development is well characterized, information on humans is scarce due to the limited availability of material. Here, we analyzed the transcriptional distribution of Mlc-2a, Mlc-1v, Mlc-2v, and atrial natriuretic factor (ANF) in human embryonic hearts between 7 and 18 weeks of gestation and in healthy and hypertrophic adult hearts by in situ hybridization and compared expression with that in mice. Strikingly, Mlc-2a, Mlc-1v, and ANF, which are essentially chamber-restricted in mice by mid-gestation, showed a broader distribution in humans. On the other hand, Mlc-2v may prove to be an adequate ventricular marker in humans in contrast to mouse. This study emphasizes the importance of careful comparative human-animal analyses during embryonic development and adulthood, as avoiding erroneous extrapolations may be critical to develop new and successful myocardial replacement therapies.
No takes yet. Share an insight, caveat, or question.
Lopes et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: